Moderna

Moderna, a US-based Pharmaceutical Preparation Manufacturing company, reported a total of approximately 1.19 billion kg CO2e in 2022. This figure comprises Scope 1 emissions of about 11.89 million kg CO2e, Scope 2 market-based emissions of approximately 225,000 kg CO2e (or 9.88 million kg CO2e using location-based reporting), and Scope 3 emissions totalling around 1.14 billion kg CO2e.

In 2021, Moderna's total emissions were approximately 401 million kg CO2e. This included Scope 1 emissions of about 9.36 million kg CO2e, Scope 2 market-based emissions of approximately 4,000 kg CO2e (or 6.95 million kg CO2e location-based), and Scope 3 emissions of around 390 million kg CO2e.

Moderna has established significant climate commitments. The company aims to achieve net-zero carbon emissions across all scopes by 2030. Furthermore, Moderna has committed to reducing absolute Scope 1 and 2 GHG emissions by 90% by 2030, using 2021 as the base year. They also aim for a 90% reduction in absolute Scope 3 GHG emissions by 2045, also from a 2021 baseline. In the long term, the commitment extends to maintaining a minimum of 90% absolute Scope 1 and 2 GHG emissions reduction from 2030 through 2045. Moderna also commits that 85% of its suppliers, covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2028.